新诺威：预计2025年度净利润亏损1.7亿元~2.55亿元

Group 1 - The company expects a net profit loss of 170 million to 255 million yuan for 2025, a significant shift from profit to loss year-on-year [1] - The primary reason for the performance change is the increased investment in research and development (R&D) to accelerate the innovation pipeline [1] - The company has made significant progress with multiple products in development, including four antibody drugs, six ADC products, and one mRNA vaccine receiving clinical trial approvals for the first time in 2025 [1] Group 2 - One monoclonal antibody product has received approval for a new indication, while another monoclonal antibody product's market application has been accepted [1] - Two ADC products have entered Phase III clinical trials, contributing to the increased R&D expenses, which are projected to reach approximately 1 billion yuan for the year, marking a substantial year-on-year increase [1]